Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Quantifying and Communicating Uncertainty in Preclinical Human Dose-Prediction.

Sundqvist M, Lundahl A, Någård MB, Bredberg U, Gennemark P.

CPT Pharmacometrics Syst Pharmacol. 2015 Apr;4(4):243-54. doi: 10.1002/psp4.32. Epub 2015 Apr 16.

2.

Model-based drug discovery: implementation and impact.

Visser SA, Aurell M, Jones RD, Schuck VJ, Egnell AC, Peters SA, Brynne L, Yates JW, Jansson-Löfmark R, Tan B, Cooke M, Barry ST, Hughes A, Bredberg U.

Drug Discov Today. 2013 Aug;18(15-16):764-75. doi: 10.1016/j.drudis.2013.05.012. Epub 2013 May 29. Review.

PMID:
23726890
3.

The pharmacokinetics and hepatic disposition of repaglinide in pigs: mechanistic modeling of metabolism and transport.

Sjögren E, Bredberg U, Lennernäs H.

Mol Pharm. 2012 Apr 2;9(4):823-41. doi: 10.1021/mp200218p. Epub 2012 Mar 6.

PMID:
22352317
4.

Optimal experimental design for assessment of enzyme kinetics in a drug discovery screening environment.

Sjögren E, Nyberg J, Magnusson MO, Lennernäs H, Hooker A, Bredberg U.

Drug Metab Dispos. 2011 May;39(5):858-63. doi: 10.1124/dmd.110.037309. Epub 2011 Feb 2.

PMID:
21289074
5.

Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.

Fridén M, Bergström F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, Bredberg U.

Drug Metab Dispos. 2011 Mar;39(3):353-62. doi: 10.1124/dmd.110.035998. Epub 2010 Dec 13.

PMID:
21149540
6.

Hepatic disposition of ximelagatran and its metabolites in pig; prediction of the impact of membrane transporters through a simple disposition model.

Sjögren E, Bredberg U, Allard E, Arvidsson B, Bergquist J, Andersson TB, Lennernäs H.

Pharm Res. 2010 Apr;27(4):597-607. doi: 10.1007/s11095-009-0016-y. Epub 2010 Feb 6.

PMID:
20140637
7.

Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.

Fridén M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, Hammarlund-Udenaes M, Antonsson M.

J Med Chem. 2009 Oct 22;52(20):6233-43. doi: 10.1021/jm901036q.

PMID:
19764786
8.

Improved measurement of drug exposure in the brain using drug-specific correction for residual blood.

Fridén M, Ljungqvist H, Middleton B, Bredberg U, Hammarlund-Udenaes M.

J Cereb Blood Flow Metab. 2010 Jan;30(1):150-61. doi: 10.1038/jcbfm.2009.200. Epub 2009 Sep 16.

9.

Development of a high-throughput brain slice method for studying drug distribution in the central nervous system.

Fridén M, Ducrozet F, Middleton B, Antonsson M, Bredberg U, Hammarlund-Udenaes M.

Drug Metab Dispos. 2009 Jun;37(6):1226-33. doi: 10.1124/dmd.108.026377. Epub 2009 Mar 19.

PMID:
19299522
10.

Methodologies to assess brain drug delivery in lead optimization.

Hammarlund-Udenaes M, Bredberg U, Fridén M.

Curr Top Med Chem. 2009;9(2):148-62.

PMID:
19200002
11.

Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.

Gabrielsson J, Dolgos H, Gillberg PG, Bredberg U, Benthem B, Duker G.

Drug Discov Today. 2009 Apr;14(7-8):358-72. doi: 10.1016/j.drudis.2008.12.011. Epub 2009 Jan 20. Review.

PMID:
19162219
12.
13.
14.

In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids.

Fridén M, Gupta A, Antonsson M, Bredberg U, Hammarlund-Udenaes M.

Drug Metab Dispos. 2007 Sep;35(9):1711-9. Epub 2007 Jun 25.

PMID:
17591680
15.

Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2.

Lindahl A, Sjöberg A, Bredberg U, Toreson H, Ungell AL, Lennernäs H.

Mol Pharm. 2004 Sep-Oct;1(5):347-56.

PMID:
16026004
16.

A new oral anticoagulant: the 50-year challenge.

Gustafsson D, Bylund R, Antonsson T, Nilsson I, Nyström JE, Eriksson U, Bredberg U, Teger-Nilsson AC.

Nat Rev Drug Discov. 2004 Aug;3(8):649-59. Review. No abstract available.

PMID:
15286732
17.

Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.

Masimirembwa CM, Bredberg U, Andersson TB.

Clin Pharmacokinet. 2003;42(6):515-28. Review.

PMID:
12793837
18.

Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.

Eriksson UG, Bredberg U, Gislén K, Johansson LC, Frison L, Ahnoff M, Gustafsson D.

Eur J Clin Pharmacol. 2003 May;59(1):35-43. Epub 2003 Mar 27.

PMID:
12743672
19.

Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans.

Eriksson UG, Bredberg U, Hoffmann KJ, Thuresson A, Gabrielsson M, Ericsson H, Ahnoff M, Gislén K, Fager G, Gustafsson D.

Drug Metab Dispos. 2003 Mar;31(3):294-305.

PMID:
12584156
20.

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.

Gustafsson D, Nyström J, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann K, Ungell A, Sörensen H, Någård S, Abrahamsson A, Bylund R.

Thromb Res. 2001 Feb 1;101(3):171-81.

PMID:
11228340
21.

Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers.

Ericsson H, Bredberg U, Eriksson U, Jolin-Mellgård A, Nordlander M, Regårdh CG.

Anesthesiology. 2000 Apr;92(4):993-1001.

PMID:
10754618
22.

Stereoselective metabolism by human liver CYP enzymes of a substituted benzimidazole.

Abelö A, Andersson TB, Bredberg U, Skånberg I, Weidolf L.

Drug Metab Dispos. 2000 Jan;28(1):58-64.

PMID:
10611141
23.

Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug.

Eriksson UG, Renberg L, Bredberg U, Teger-Nilsson AC, Regårdh CG.

Biopharm Drug Dispos. 1998 Jan;19(1):55-64.

PMID:
9510985
24.
25.
26.
28.

Pharmacokinetics of methysergide and its metabolite methylergometrine in the rat.

Bredberg U, Paalzow L.

Drug Metab Dispos. 1990 May-Jun;18(3):338-43.

PMID:
1974196
29.

Bioavailability estimation by semisimultaneous drug administration: a Monte Carlo simulation study.

Karlsson MO, Bredberg U.

J Pharmacokinet Biopharm. 1990 Apr;18(2):103-20.

PMID:
2348378
30.
31.
32.

Clinical case definition of AIDS in African adults.

Pallangyo KJ, Mbaga IM, Mugusi F, Mbena E, Mhalu FS, Bredberg U, Biberfeld G.

Lancet. 1987 Oct 24;2(8565):972. No abstract available.

PMID:
2889892
33.

A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II, and HTLV-IIIB.

Albert J, Bredberg U, Chiodi F, Böttiger B, Fenyö EM, Norrby E, Biberfeld G.

AIDS Res Hum Retroviruses. 1987 Spring;3(1):3-10.

PMID:
3040053
34.

Pharmacokinetics of methysergide and its metabolite methylergometrine in man.

Bredberg U, Eyjolfsdottir GS, Paalzow L, Tfelt-Hansen P, Tfelt-Hansen V.

Eur J Clin Pharmacol. 1986;30(1):75-7.

PMID:
3709634

Supplemental Content

Loading ...
Support Center